Latanoprost Mylan eye drops, solution ENG SmPC
... Latanoprost Mylan has no or negligible influence on the ability to drive and use machines. However, in common with other eye preparations, instillation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines. ...
... Latanoprost Mylan has no or negligible influence on the ability to drive and use machines. However, in common with other eye preparations, instillation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines. ...
file (Appropriate Selection of a 2nd Generation
... clinically significant as reflected by the ADA Consensus Guidelines, which recommend against the use of glyburide when initiating a sulfonylurea as add-on therapy. The potential risk for increased hypoglycemia with glyburide is most likely linked to its pharmacokinetic profile. Glyburide has a longe ...
... clinically significant as reflected by the ADA Consensus Guidelines, which recommend against the use of glyburide when initiating a sulfonylurea as add-on therapy. The potential risk for increased hypoglycemia with glyburide is most likely linked to its pharmacokinetic profile. Glyburide has a longe ...
Epilim (Sodium Valproate)
... (see aspirin/salicylate product information on Reye’s syndrome). Monotherapy is recommended in children under the age of 3 years when prescribing Epilim, but the potential benefit of Epilim should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of the ...
... (see aspirin/salicylate product information on Reye’s syndrome). Monotherapy is recommended in children under the age of 3 years when prescribing Epilim, but the potential benefit of Epilim should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of the ...
product monograph
... opinion of the physician, the expected benefit to the patient outweighs the potential risk to the fetus or child. Pediatrics (< 18 years): Since the safety and efficacy of flupentixol in children has not been established, its use is not recommended in the pediatric age group. ...
... opinion of the physician, the expected benefit to the patient outweighs the potential risk to the fetus or child. Pediatrics (< 18 years): Since the safety and efficacy of flupentixol in children has not been established, its use is not recommended in the pediatric age group. ...
Itraconazole
... drug or any ingredient in the formulation. Patients who have severe hepatic disease are not advised to take Itraconazole. It is not advisable to use the drug in patients taking rifampin, which appears to initially inhibit and then enhance the metabolism of Itraconazole. PRECAUTION Absorption is impa ...
... drug or any ingredient in the formulation. Patients who have severe hepatic disease are not advised to take Itraconazole. It is not advisable to use the drug in patients taking rifampin, which appears to initially inhibit and then enhance the metabolism of Itraconazole. PRECAUTION Absorption is impa ...
Inglés
... 20 mcg/ml concentration inhibits ameba growth and motility. This drug controls ameba propagation. On animal testing it has been demonstrated that oral administration for 3 days has eliminated Entamoeba criceti from hamster’s bowel. Quinfamide showed to be more effective than etofimate, diloxamide an ...
... 20 mcg/ml concentration inhibits ameba growth and motility. This drug controls ameba propagation. On animal testing it has been demonstrated that oral administration for 3 days has eliminated Entamoeba criceti from hamster’s bowel. Quinfamide showed to be more effective than etofimate, diloxamide an ...
Side-effects of antituberculosis drug treatment in patients with chronic renal failure
... the current authors found that the dose of isoniazid used varied from 100–300 mg?day-1 and sometimes varied according to body weight [18]. The dose of pyridoxine also varied from 10 to 50 mg?day-1. Pyridoxine in a dose of 100 mg?day-1 has been recommended to prevent neurological side effects of ison ...
... the current authors found that the dose of isoniazid used varied from 100–300 mg?day-1 and sometimes varied according to body weight [18]. The dose of pyridoxine also varied from 10 to 50 mg?day-1. Pyridoxine in a dose of 100 mg?day-1 has been recommended to prevent neurological side effects of ison ...
Drugs Salbutamol (Ventolin) SLB
... Salbutamol is less effective in children <12 months and a single dose of 2.5 milligrams should be administered. If this is ineffective, further doses should not be given. In severe attacks nebulisation may need to be repeated as necessary. The pulse rate in children may exceed 140 after significant ...
... Salbutamol is less effective in children <12 months and a single dose of 2.5 milligrams should be administered. If this is ineffective, further doses should not be given. In severe attacks nebulisation may need to be repeated as necessary. The pulse rate in children may exceed 140 after significant ...
22-7. Antibacterials
... They are active against organisms inhibited by first-generation drugs, but in addition they have extended Gramnegative coverage. Klebsiellae (incl. those resistant to cefalotin) are usually sensitive. Cefamandole, cefuroxime, and cefaclor are active against H. influenzae but not against serratia or ...
... They are active against organisms inhibited by first-generation drugs, but in addition they have extended Gramnegative coverage. Klebsiellae (incl. those resistant to cefalotin) are usually sensitive. Cefamandole, cefuroxime, and cefaclor are active against H. influenzae but not against serratia or ...
PHYSICIANS CIRCULAR Tablets Co-Novatec (lisinopril and
... amiloride), potassium supplements, or potassium-containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalem ...
... amiloride), potassium supplements, or potassium-containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalem ...
Ampicillin - IARC Monographs on the Evaluation of Carcinogenic
... ampicilin of glandular fever and lymphatic leukaemia (Cameron & Richmond, 1971; Lambert et aL., 1972). ...
... ampicilin of glandular fever and lymphatic leukaemia (Cameron & Richmond, 1971; Lambert et aL., 1972). ...
New oral anticoagulants in severe trauma patients: Enemy at the
... phenomena.9 In this regard, we have established the main advantages and problems associated with the use of vitamin K antagonists. As positive aspects, mention must be made of their reasonable cost, good efficacy, the possibility of knowing their effects upon coagulation, the development of point of ...
... phenomena.9 In this regard, we have established the main advantages and problems associated with the use of vitamin K antagonists. As positive aspects, mention must be made of their reasonable cost, good efficacy, the possibility of knowing their effects upon coagulation, the development of point of ...
Table 5. Matching Antidepressants to Patients
... If a patient fails one SSRI class of antidepressants, another SSRI may tried (don't try a third SSRI). During the initial phase of treatment all SSRI's may produce one or all of the following: Increased arousal (agitation), insomnia, nausea, diarrhea (due to increased GI motility), initial weight lo ...
... If a patient fails one SSRI class of antidepressants, another SSRI may tried (don't try a third SSRI). During the initial phase of treatment all SSRI's may produce one or all of the following: Increased arousal (agitation), insomnia, nausea, diarrhea (due to increased GI motility), initial weight lo ...
Document
... t 1/2 = ~24 hours Cmax (400 mg IV) = 20 µg/ml (steady state) Protein binding < 12% Vd 0.85 L/kg (widely distributed) >90% excreted unchanged through the kidney ...
... t 1/2 = ~24 hours Cmax (400 mg IV) = 20 µg/ml (steady state) Protein binding < 12% Vd 0.85 L/kg (widely distributed) >90% excreted unchanged through the kidney ...
Efficacy and Safety of Micafungin for Febrile Neutropenia in
... Moreover, because azole antifungal agents are known to inhibit cytochrome P450 3A (CYP3A) enzymes,21 physicians must pay attention to the other drugs being used by their patients when starting azole therapy. MCFG is an echinocandin antifungal agent, that inhibits the synthesis of 1,3-b-D-glucan in t ...
... Moreover, because azole antifungal agents are known to inhibit cytochrome P450 3A (CYP3A) enzymes,21 physicians must pay attention to the other drugs being used by their patients when starting azole therapy. MCFG is an echinocandin antifungal agent, that inhibits the synthesis of 1,3-b-D-glucan in t ...
Suggestion from clinicians
... is a high risk of bias in the metabolic data. This review does not provide a good assessment of the adverse effects of these drugs because there was a high risk of bias in the reporting of withdrawals due to adverse effects. This systematic review shows that hydrochlorothiazide has a dose-related bl ...
... is a high risk of bias in the metabolic data. This review does not provide a good assessment of the adverse effects of these drugs because there was a high risk of bias in the reporting of withdrawals due to adverse effects. This systematic review shows that hydrochlorothiazide has a dose-related bl ...
product monograph
... Patients with Parkinson’s Disease: Flupentixol should be used with caution in patients with Parkinsonism, as it is known that dopamine antagonists such as flupentixol, can cause a deterioration of the disease. Seizures: Flupentixol should be used with caution in patients with a history of convulsiv ...
... Patients with Parkinson’s Disease: Flupentixol should be used with caution in patients with Parkinsonism, as it is known that dopamine antagonists such as flupentixol, can cause a deterioration of the disease. Seizures: Flupentixol should be used with caution in patients with a history of convulsiv ...
posure to injectable cephalosporins were selected for
... one of reacting to an orally administered cephalosporin, it is probably even likelier that the parenteral agent would be well-tolerated. However, because most severe reactions follow injected drug at any age, it would be wise to skin test with the desired injectable cephalosporin first. Finally, the ...
... one of reacting to an orally administered cephalosporin, it is probably even likelier that the parenteral agent would be well-tolerated. However, because most severe reactions follow injected drug at any age, it would be wise to skin test with the desired injectable cephalosporin first. Finally, the ...
452صيد
... Absorption: absorbed rapidly after oral administration. Small portion is metabolized on its first pass through the liver. Average bioavilability is 70% when compaired to IV injection. 19% bound to serum protein (Vd = 1.5 L/kg) 48% is excreted unchanged in urine (t½ = 2-3 hrs) ...
... Absorption: absorbed rapidly after oral administration. Small portion is metabolized on its first pass through the liver. Average bioavilability is 70% when compaired to IV injection. 19% bound to serum protein (Vd = 1.5 L/kg) 48% is excreted unchanged in urine (t½ = 2-3 hrs) ...
SUMMARY OF PRODUCT CHARACTERISTICS 4 CLINICAL
... administered either in single or divided doses is significantly less irritating to the gastrointestinal tract than aspirin. Some epidemiological studies have suggested that ...
... administered either in single or divided doses is significantly less irritating to the gastrointestinal tract than aspirin. Some epidemiological studies have suggested that ...
Therapeutic Parenteral Drug Administration and In
... pain. In this study, patients developing moderate -to-severe pain after third molar extraction under local anesthesia were randomized to one of the 4 SC injections: 25, 50, or 75 mg diclofenac, or placebo. The pain intensity differences were measured at 1.5 hours post dose and showed was higher in ...
... pain. In this study, patients developing moderate -to-severe pain after third molar extraction under local anesthesia were randomized to one of the 4 SC injections: 25, 50, or 75 mg diclofenac, or placebo. The pain intensity differences were measured at 1.5 hours post dose and showed was higher in ...
SPARC Investor Presentation - sun pharma advanced research
... nm taken on a Malvern’s Zetasizer. ...
... nm taken on a Malvern’s Zetasizer. ...
Xofigo Patient Treatment Guide
... • stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst) or urinary or kidney problems (such as burning when urinating) • there are no restrictions regarding contact with other people after receiving Xofigo • follow good hygiene practices in order to minim ...
... • stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst) or urinary or kidney problems (such as burning when urinating) • there are no restrictions regarding contact with other people after receiving Xofigo • follow good hygiene practices in order to minim ...
Sinarest LP Tab/Susp
... ♦ Paracetamol may increase chloramphenicol concentrations ♦ The risk of paracetamol toxicity may be increased in patients receiving other hepatotoxic drugs or drugs that induce liver microsomal enzymes such as alcohol and anticonvulsant agents ♦ Paracetamol excretion may be affected when given with ...
... ♦ Paracetamol may increase chloramphenicol concentrations ♦ The risk of paracetamol toxicity may be increased in patients receiving other hepatotoxic drugs or drugs that induce liver microsomal enzymes such as alcohol and anticonvulsant agents ♦ Paracetamol excretion may be affected when given with ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.